Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

ent $- $- $- $- $174

License revenue 22 22 66 66 331

Total revenues 22 22 66 66 505

Operating expenses:

Research and

development 21,463 12,938 61,735 33,215 151,592

General and

administrative 3,638 2,694 11,049 7,402 33,220

Total operating

expenses 25,101 15,632 72,784 40,617 184,812

Loss from operations (25,079) (15,610) (72,718) (40,551) (184,307)

Other income (expense):

Interest income 662 1,322 2,800 2,800 8,364

Interest expense (370) (260) (1,196) (596) (2,106)

Total other income

(expense) 292 1,062 1,604 2,204 6,258

Net loss (24,787) (14,548) (71,114) (38,347) (178,049)

Accretion to redemption

value of redeemable

convertible preferred

stock - - - (11) (78)

Deemed dividend of

beneficial conversion

for Series C preferred

stock - - - - (13,860)

Net loss attributable

to common

stockholders $(24,787) $(14,548) $(71,114) $(38,358) $(191,987)

Net loss per share

attributable to

common stockholders

- basic and diluted $(0.72) $(0.54) $(2.12) $(2.40)

Shares used in

computing net loss

per share attributable

to common stockholders

- basic and diluted 34,355 26,905 33,539 16,003


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/28/2015)... ZIONA, Israel , ... Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing ... products, today announced that Shomrat Shurtz has been ... 20, 2015.      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ... over 25 years of experience in marketing, regulatory ...
(Date:7/27/2015)... Tenn. , July 27, 2015  Capella ... care services and one of the largest for-profit ... its parent company and sole stockholder, Capella Holdings, ... Properties Trust, Inc. ("MPT") (NYSE: MPW ) ... The transaction is expected to be finalized during ...
(Date:7/27/2015)... ... 27, 2015 , ... Production of high tenacity filament yarn of viscose rayon ... EU. For instance, it surpassed the EUR 106 million mark (in value terms) in ... is a major producer, while Italy is a key consumer. , The high ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... A new Oak Ridge National Laboratory initiative could ... and also lead to more information about climate change. ... will be implemented in Gulfport, Miss., Memphis, and Charleston, ... for, respond to and quickly recover from natural and ...
... combining two materials to make a composite material with ... a mainstay of the marine industry for decades and ... carbon nanotubes (CNT) are getting in on the act ... for polymers in an ideal manner. , Researchers ...
... Calif., Nov. 21 Accuray,Incorporated (Nasdaq: ARAY ), ... that its president and chief executive officer, Euan S.,Thomson, ... Piper,Jaffray,s Health Care Conference at the Pierre Hotel in ... p.m. EST (9:30 a.m. PST)., A live webcast ...
Cached Biology Technology:ORNL 'resilience' plan to help Tennessee, Mississippi and South Carolina communities beat disaster 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 2Accuray Incorporated's CEO to Speak at Piper Jaffray 19th Annual Health Care Conference 3
(Date:7/7/2015)... OXFORD, Conn. , July 7, 2015 NXT-ID, Inc. ... company focused on the growing mobile commerce market announces a revised ... airing this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2
... The U.S. Food & Drug Administration (FDA) has granted Investigational ... clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, ... University of the Negev. This is the first time ... AAT is an FDA-approved off-patent drug currently used to treat ...
... The Netherlands believe they are on the verge of ... able to detect accurately chromosomal abnormalities in the developing ... this is through amniocentesis or chorionic villus sampling, both ... triggering a miscarriage. Dr Suzanna Frints, a clinical ...
... wildfires and influxes of pollutants create disturbances that ... Ecologists had believed that at times like these, ... struggle to survive. But a new laboratory ... of acoustic disturbance now challenges that assumption ...
Cached Biology News:FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 3Study challenges long-held assumption about competition in disturbed ecosystems 2Study challenges long-held assumption about competition in disturbed ecosystems 3Study challenges long-held assumption about competition in disturbed ecosystems 4
... with a variety of motion options - ... one unit. Shake, rock, roll and rotate ... for hybridization and blotting procedures requiring different ... upper chamber uses a roller action to ...
... Concentrator, the SPD series takes the 'Classic' ... twist., The SPD121P SpeedVac comes equipped with ... runs; preventing samples from freezing; and allowing ... end-users preset level., Standard features on the ...
... are designed to create the ideal environment for ... to 99.9C) , Variable speed control (10 ... whether it be for washing or hybridizing ... temperature inside the chamber, ,is situated above a ...
... Express is the latest edition to the ... has an extra large diameter exhaust port ... display panel allows precise setting and control ... for handling large quantities and samples ...
Biology Products: